The Pharma Data

APRIL 8, 2021

“Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Therapies 52

Therapies Disease Research Laboratories Treatment 52

The Pharma Data

SEPTEMBER 1, 2021

If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.”.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

The Pharma Data

JUNE 25, 2021

We hope to build on this important research and provide new treatment options to kidney cancer patients.”. “As The late-breaking results will be presented in the Plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA5) on Sunday, June 6, 2021.

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

MARCH 17, 2021

“The European Commission’s approval of an expanded use of KEYTRUDA provides another option for adult and pediatric patients with classical Hodgkin lymphoma who have disease progression after earlier lines of therapy or relapse after transplantation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. “We

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

MARCH 16, 2021

In fact, up to 70% of patients with VHL develop renal cell carcinoma during their lifetime,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. Research into VHL biology that led to the discovery of HIF-2? was awarded the Nobel Prize in Physiology or Medicine in 2019.

FDA 52

FDA Disease Trials Drugs 52

The Pharma Data

SEPTEMBER 7, 2021

“In China, esophageal and gastroesophageal junction cancers are leading causes of death, and there have been few treatment advances for patients over the past several decades,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

The Pharma Data

JUNE 29, 2021

“KEYTRUDA plus chemotherapy is the first anti-PD1 therapy approved in Europe in this first-line setting, allowing these patients to be treated with immunotherapy earlier in the course of their treatment,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

Therapies 52

Therapies Treatment Disease Clinical Research 52

The Pharma Data

JULY 15, 2021

“These highly anticipated event-free survival results in this TNBC population build upon earlier findings from the KEYNOTE-522 trial and further support the potential use of KEYTRUDA in these patients,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories.

Therapies 52

Therapies Treatment Trials FDA 52

The Pharma Data

MARCH 30, 2021

“KEYTRUDA has become an important treatment option for certain patients with locally advanced or metastatic bladder cancer in the European Union and other countries around the world,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

DECEMBER 17, 2020

He previously spent more than a decade at Medtronic in the company ’ s Minimally Invasive Therapies Group where he served as the global vice president and General Manager of General Surgery, and in various roles working on research, development, and strategy. He spent 27 years at Merck & Co. Immune Regulation – U.K.-based

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

JULY 6, 2021

“While there remains an unmet need for heavily pre-treated patients with advanced gastric cancer, we recognize that the treatment landscape has evolved and we respect the FDA’s efforts to continually evaluate accelerated approvals,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

PPD

OCTOBER 12, 2023

Emerging areas of pharmaceutical research not only bring novel opportunities but also new regulatory guidance. It is this kind of familiarity and knowledge of FDA filings that an experienced provider can offer their clients to save both time and money, while avoiding bottlenecks with future filings.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

JULY 8, 2021

KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

JULY 22, 2021

Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories.

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

AUGUST 15, 2021

“WELIREG is the first and only approved systemic therapy for patients with certain types of VHL-associated tumors, representing an important new treatment option for patients affected by this rare condition,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

MARCH 23, 2021

“There have been few advances in improving survival outcomes in the first-line treatment setting for esophageal cancer over the last three decades,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We

Treatment 52

Treatment FDA Approval FDA Therapies 52

The Pharma Data

APRIL 4, 2023

Merck has the industry’s largest immuno-oncology clinical research program. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Treatment 40

Treatment FDA Approval FDA Therapies 40

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. Merck’s Commitment to HIV.

Trials 52

Trials Clinical Trials International Production 52

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Oncologist Kerry Reynolds (left) and researcher Alexandra-Chloé Villani (right) work together to better understand and treat complications of immunotherapy. We started by bringing in subspecialties to think about best practices for clinical care and to devise research questions to ask.

Research 131

Research Immune Response Hospitals Therapies 131